

Docket No.: 0933-0246PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Juha KUJA-PANULA et al.

Application No.: 10/537,102

Filed: June 2, 2005

For: THE TRANSMEMBRANE PROTEIN AMIGO

AND USES THEREOF

Confirmation No.: 2142

Art Unit: 1642

Examiner: Not Yet Assigned

STATUS INQUIRY REGARDING ASSIGNMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the attorney named below be advised of the status of the above-identified application. Please advise us of when we might expect to receive the Notice of Recordation of Assignment Document from the Patent and Trademark Office.

Dated:

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

IRECEIVED

Birch, Stewart, Kolasch & Birch, LLP

GMM/TJS/mao



Docket No.: 0933-0246PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Juha KUJA-PANULA et al.

Application No.: 10/537,102

Confirmation No.: 2142

Filed: June 2, 2005

Art Unit: 1642

For: THE TRANSMEMBRANE PROTEIN AMIGO

AND USES THEREOF

Examiner: Not Yet Assigned

RESPONSE TO NOTICE TO COMPLY

MS Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

On December 15, 2005 the U.S. Patent and Trademark Office mailed to Applicant's representative a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

A Second Preliminary Amendment is attached hereto submitting a clean copy and marked-up copy of the Substitute Specification and Substitute Sequence Listing (paper copy and CRF disk copy) in the above-identified application in order to comply with the requirements of the Notice.

FEB 14, 2835

RECEIVED

Application No.: 10/537,102 Docket No.: 0933-0246PUS1

An application size fee was paid with the filing of the original application to cover up to 245 pages. Therefore, it is believed that no additional fee is necessary at this time. However, if necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: February 10, 2006

Respectfully submitted,

Gerald M. Murphy, Jr.

Registration No.: 28,977

BIRCH, \$TEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road

Suite 100 East

P.O. Box 747


Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

Attachments: Copy of Notice to Comply

Second Preliminary Amendment w/attachments



Date Mailed: 12/15/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

OC000000017634759

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

CHARITTA A BURT

Telephone: (703) 308-9140 EXT 207

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/537,102	PCT/FI03/00949	0933-0246PUS1

FORM PCT/DO/EO/922 (371 Formalities Notice)